This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Qurient Co., Ltd.
Drug Names(s): Q203
Description: Q203 is an orally available potent anti-tuberculosis drug candidate that shows activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis. Q203 is a first-in-class agent with novel mode of action through blocking cytochrome bc1 complex.
Infectex and Qurient
In February 2014, Infectex and Qurient have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurients Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine.
Additional information available to subscribers only: